CDR-Life Inc.’s Post

🚀 Exciting News from the Swiss Biotech Sector! 🚀 📈 Record revenues of CHF 7.3 billion 💰 Capital investments surge by over 50% 🔬 Significant licensing and M&A activity, including CRISPR gene editing therapy 💡 Swiss Biotech Report highlights industry resilience and global impact 🌍 Expansion of Global Village platform fosters international collaboration 🏆 Swiss Biotech Success Stories Awards honor trailblazing contributions See the link below to download the report & do not hesitate to reach out with any questions about Biotech investments in Switzerland 🇨🇭 #SwissBiotech #EY #BuildingABetterWorkingWorld

Biopharma's Evolution: Precision medicine and gene therapies reshape healthcare. Strategic investments by venture capitalists translate research into transformative solutions, positioning us as architects of a healthier future. #pharma #pharmaceutical #healthcare #venturecapital #investment #biopharma

Short-term impact of Biotech and CROs like ourselves. See the pdf below for full details. Short term future looks positive. The biotech landscape is swiftly evolving, with a recent survey of 150 emerging biotech executives, conducted by BioPharma Dive and Cytiva, revealing keen insights into the future of CRO and CDMO partnerships. Amidst complex challenges like manufacturing intricacies and market pressures, there's a clear call for enhanced outsourcing relationships. Key findings include a notable drive towards advanced therapies, such as cell and gene therapies and monoclonal antibodies, yet there's a marked gap in confidence regarding manufacturing capacity for 2024. This scenario presents an opportunity for CROs and CDMOs to step up with solutions like process automation and modular facilities. Market and data concerns, including rising interest rates and labor shortages, underscore the growing importance of strategic outsourcing partnerships with companies such as ourselves. Biotechs highly value data analytics, regulatory expertise, and competitive pricing in their partners. Although satisfaction with current partners is high, there's a universal appetite for improvements in time efficiency and cost transparency. The survey underlines a positive moment for CROs and CDMOs to align closely with biotech needs, offering a chance to differentiate and cement their value in facilitating biotech advancements. For more insights, visit Cytiva's Biopharma Dive. #BiotechTrends #CROPartnerships #CDMOPartnerships #OutsourcingEvolution #InnovationInBiotech #RegulatoryExpertise #DataAnalyticsInBiotech

Wrapped up in our coziest coats, we unwrapped an early Christmas present at the Advanced Therapies Integrates 2023 event in a frosty Stevenage, UK. Huge thanks to the organizers, Life Science Integrates, and supporters including Stevenage Bioscience Catalyst, Cytiva, and Cell and Gene Therapy Catapult, among others, for orchestrating this focused networking event that seamlessly brought together stakeholders spanning the entire drug development cycle. Amidst delightful coffee and delicious food, we engaged with representatives from big pharma, patient advocates, CDMOs, fellow consultants, clinicians, researchers, early-stage developers, biotech and pharma professionals, regulators, market access experts, and various other industry players. Hot topics of discussion included closed systems and automation, with a common agreement that well-characterized, consistent processes are prerequisites for successful automation. The discussion also delved into exciting applications of AI and advanced software to support the NHS workforce and enhance operational efficiencies, with a caveat for cautious implementation. Gene People and Opie Jones Foundation brought invaluable patient perspectives into the discourse, emphasizing that the costs of new therapies should consider the alternatives of no or limited treatment options. Cytiva and the Cell and Gene Therapy Catapult provided lab tours, offering developers insights into processes and feasibility before embarking on manufacturing runs. This aids in cost management and risk mitigation. Investors, beyond seeking breakthrough science, actively seek enthusiasm, perseverance, and responsiveness in early-stage biotechs. The imperative of closely tracking your company’s value and inflection points was underscored. Understanding the investor perspective involves placing yourself in their shoes. Lindville Bio shared insights into iPSC therapeutic development. With sights set on the horizon, we eagerly anticipate the next edition of Advanced Therapies Integrates in 2024! #Advancedtherapiesintegrates2023 #Biotech #DrugDevelopment #Innovation #networkingsuccess #iPSC #stemcells #celltherapy #regenerativemedicine #biotech #biotechnology #lifescience #advancedtherapies #ATMP #genetherapy #raredisease #pharma #pharmaceuticals #biopharma

Watch as Mike Ward and Matthew Arnold discuss trends to watch in life sciences and healthcare, including the increase of high-valued partnering deals centered on preclinical assets in the pharma industry. They note, "The biotech sector has returned to pre-pandemic fundraising and deal-making norms. During the pandemic, biotech and biopharma were the month's flavor because of the efforts they've been making to take on that challenge. In contrast, we're now in a sort of hangover period. Still, there are some green shoots." Pharmas will now have to replenish their portfolios with innovative medicines and new technologies like ADCs and gene editing. Read more: https://ow.ly/me3150QiMWz #biotech #pharma #partnership #trendstowatch

Mike and Matt discuss the first of our trends to watch in life sciences and healthcare.

During the last Festival of Biologics in San Diego, I had numerous conversations about the role of AI in antibody design and development. It's clear that for many, AI still feels like a magical black box. If you're curious about how AI can enhance your work in optimizing antibodies, I invite you to read our recent blog post. It provides an overview of validated approaches that make a difference in this field. 🔗 Check it out here: AI-Powered Breakthroughs in Antibody Optimization https://lnkd.in/dbzitbdF Feel free to reach out if you’d like to dive deeper into this topic. I’m here to continue the conversation and explore how we can leverage AI together for the discovery of biological therapeutics! #AI #ArtificialIntelligence #Antibody #Biotechnology #DrugDiscovery #Festivalofbiologics #Ardigen

This is a very nice article on gectosomes (also called "gesicles" by other groups 🤔). The discussion of how this technology compares to natural exosomes for intracellular cargo delivery is particularly good. As potential therapeutics, gectosomes seem more amenable to large-scale manufacturing and seem more "engineerable" for different applications than exosomes, in my opinion.

Integrins as Drug Targets – Time for a Renaissance? Two pivotal changes have marked my recent journey: transitioning from academia and diving deep into current trends in the biopharmaceutical industry. And after a while, I started to wonder: Why is there not more talk about integrins? These major cell adhesion receptors are found in all animals and were the cornerstone of my research career. At the same time, they hold immense potential as drug targets. Especially exciting is their potential in new modalities like antibody-drug conjugates (ADCs), radioligand therapy (RLT), and gene therapy. These are topics where many Swiss startups are engaged and where integrins could be valuable targets. I’m excited to share insights from my fundamental science background about integrins' pros and cons as drug targets from my perspective. Follow me in the coming days for a deeper dive, and feel free to share your thoughts and feedback. Looking forward to engaging discussions! #Biopharma #DrugDevelopment #Integrins #ADCs #RadioligandTherapy #GeneTherapy #Startups #Innovation #Pharmaceuticals #LifeSciences #Biotech

3 Insights from Engaging with Partners and Prospects at xcube.bio : Since the launch of xcube.bio, we've had insightful discussions with many executives from late clinical-stage biotech companies. When exploring commercialization opportunities in Europe, three recurring themes have emerged : The Importance of a Clear Narrative for the European Pharma Market : The European market is viewed as both appealing and risky, familiar yet unknown. This duality is a reality, given the complexities of market entry and its fragmentation. While the region boasts a large pool of patients, medical centers of excellence, and high standards of care, there's a need for a more articulate explanation of the path forward, including milestones and expectations. Exploring Diverse Commercialization Options: There's a growing consensus that current go-to-market models for many assets fall short in terms of risk management, value sharing, asset control, and cost efficiency. The diverse landscape of therapeutic modalities, such as gene therapy, CAR-T, and radiolabeled antibodies, coupled with the increasing specificity of target patients, necessitates purpose-built commercial capabilities. Being part of a mixed commercial portfolio is providing diminishing synergies. Resistance to Long-Term Commitments with Partners: Given the ongoing uncertainties in the industry, biopharma innovators are understandably hesitant to enter long-term commitments with partners. Retaining oversight and optionality on asset commercialization allows flexibility to pivot in response to future developments. As a commercial-stage incubator, xcube.bio has an ability to navigate the current biotech landscape. This experience continually inspires us to update our model, ensuring we deliver even more value to biotech partners. #biotech #biotechnology #healthcare #biopharma #technology #incubator #emergingbiopharma #launch